Abstract
To date, no effective treatment is available for advanced cancers, which remain a major cause of morbidity and mortality. Clearly, there is urgent need to unravel novel biomarkers for early detection. Proteomic approaches for the identification of novel biomarkers for cancer diagnosis and staging have traditionally relied on the identification of differentially expressed proteins between tumour cells and their normal counterparts based on the patterns of protein expression observed by two-dimensional gel electrophoresis (2DE-PAGE). Recent advances in mass spectrometry and bioinformatics and statistical algorithms necessary to interpret mass spectrometric data have revolutionized the approach to defining new tumour markers. Proteomics studies have generated numerous datasets of potential prognostic, diagnostic and therapeutic significance in human cancer. In this review we will discuss the available proteomic technologies their limitations and highlight the key areas of research required for understanding the aetiology of cancer and how they have been used to discover cancer biomarkers.
Keywords: Biomarkers, MALDI-TOF, mass spectrometry, 2DE gels, cancer
Current Cancer Therapy Reviews
Title: Application of Proteomics to the Discovery of Cancer Biomarkers
Volume: 4 Issue: 2
Author(s): Murrium Ahmad and Balwir Matharoo-Ball
Affiliation:
Keywords: Biomarkers, MALDI-TOF, mass spectrometry, 2DE gels, cancer
Abstract: To date, no effective treatment is available for advanced cancers, which remain a major cause of morbidity and mortality. Clearly, there is urgent need to unravel novel biomarkers for early detection. Proteomic approaches for the identification of novel biomarkers for cancer diagnosis and staging have traditionally relied on the identification of differentially expressed proteins between tumour cells and their normal counterparts based on the patterns of protein expression observed by two-dimensional gel electrophoresis (2DE-PAGE). Recent advances in mass spectrometry and bioinformatics and statistical algorithms necessary to interpret mass spectrometric data have revolutionized the approach to defining new tumour markers. Proteomics studies have generated numerous datasets of potential prognostic, diagnostic and therapeutic significance in human cancer. In this review we will discuss the available proteomic technologies their limitations and highlight the key areas of research required for understanding the aetiology of cancer and how they have been used to discover cancer biomarkers.
Export Options
About this article
Cite this article as:
Ahmad Murrium and Matharoo-Ball Balwir, Application of Proteomics to the Discovery of Cancer Biomarkers, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310089
DOI https://dx.doi.org/10.2174/157339408784310089 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Assortment of Human Amniotic Membrane and Curcumin: a Potential Therapeutic Strategy for Burn Wound Healing
Current Drug Therapy MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews An Overview on the Importance of Combining Complementary Analytical Platforms in Metabolomic Research
Current Topics in Medicinal Chemistry Tissue Transport of Anti-cancer Drugs
Current Pharmaceutical Design Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome
Anti-Cancer Agents in Medicinal Chemistry Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues
Drug Metabolism Letters Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets cAMP-Mediated Regulation of CYP Enzymes and Its Application in Chemotherapy
Drug Metabolism Letters Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery